Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Pfisterer

Showing results (51-60 of 76) with videos related to

Pageof 8
Sort By:
Journal of Cardiac Failure|January 11, 2015
Differential prognostic impact of resting heart rate in older compared with younger patients with chronic heart failure--insights from TIME-CHFMarzena Zurek, Micha T Maeder, Hans Rickli, et al.
European Heart Journal|June 12, 2004
Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina--on-treatment analysis of the TIME trialChristoph Kaiser, Gabriela M Kuster, Paul Erne, et al.
American Heart Journal|September 21, 2015
Improved outcomes of elderly patients treated with drug-eluting versus bare metal stents in large coronary arteries: results from the BAsel Stent Kosten-Effektivitäts Trial PROspective Validation Examination randomized trialDavid J Kurz, Alain M Bernheim, David Tüller, et al.
European Heart Journal. Acute Cardiovascular Care|May 12, 2016
Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BAsel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-studyKotaro Nochioka, Tor Biering-Sørensen, Kim Wadt Hansen, et al.
Cardiovascular Therapeutics|September 24, 2016
Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluationRainer Zbinden, Stefanie von Felten, Bastian Wein, et al.
Herz|April 2, 2004
Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS IISigmund Silber, Jaap Hamburger, Eberhard Grube, et al.
JACC. Cardiovascular Imaging|September 22, 2014
Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudyMichael J Zellweger, Michael Maraun, Hans H Osterhues, et al.
European Journal of Heart Failure|February 6, 2020
Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trialRobert Stöhr, Vincent M Brandenburg, Gunnar H Heine, et al.
The American Journal of Cardiology|October 30, 2016
Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials)Tannas Jatene, Tor Biering-Sørensen, Kotaro Nochioka, et al.
American Heart Journal|February 28, 2016
Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trialGiuseppe Vassalli, Catherine Klersy, Stefano De Servi, et al.
Pageof 8

Showing results (51-60 of 76) with videos related to

Sort By:
Pageof 8
Journal of Cardiac Failure|January 11, 2015
Differential prognostic impact of resting heart rate in older compared with younger patients with chronic heart failure--insights from TIME-CHFMarzena Zurek, Micha T Maeder, Hans Rickli, et al.
European Heart Journal|June 12, 2004
Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina--on-treatment analysis of the TIME trialChristoph Kaiser, Gabriela M Kuster, Paul Erne, et al.
American Heart Journal|September 21, 2015
Improved outcomes of elderly patients treated with drug-eluting versus bare metal stents in large coronary arteries: results from the BAsel Stent Kosten-Effektivitäts Trial PROspective Validation Examination randomized trialDavid J Kurz, Alain M Bernheim, David Tüller, et al.
European Heart Journal. Acute Cardiovascular Care|May 12, 2016
Long-term outcomes in patients with rheumatologic disorders undergoing percutaneous coronary intervention: a BAsel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination (BASKET-PROVE) sub-studyKotaro Nochioka, Tor Biering-Sørensen, Kim Wadt Hansen, et al.
Cardiovascular Therapeutics|September 24, 2016
Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents-A clinical and health-economic evaluationRainer Zbinden, Stefanie von Felten, Bastian Wein, et al.
Herz|April 2, 2004
Direct stenting with TAXUS stents seems to be as safe and effective as with predilatation. A post hoc analysis of TAXUS IISigmund Silber, Jaap Hamburger, Eberhard Grube, et al.
JACC. Cardiovascular Imaging|September 22, 2014
Progression to overt or silent CAD in asymptomatic patients with diabetes mellitus at high coronary risk: main findings of the prospective multicenter BARDOT trial with a pilot randomized treatment substudyMichael J Zellweger, Michael Maraun, Hans H Osterhues, et al.
European Journal of Heart Failure|February 6, 2020
Limited role for fibroblast growth factor 23 in assessing prognosis in heart failure patients: data from the TIME-CHF trialRobert Stöhr, Vincent M Brandenburg, Gunnar H Heine, et al.
The American Journal of Cardiology|October 30, 2016
Frequency of Cardiac Death and Stent Thrombosis in Patients With Chronic Obstructive Pulmonary Disease Undergoing Percutaneous Coronary Intervention (from the BASKET-PROVE I and II Trials)Tannas Jatene, Tor Biering-Sørensen, Kotaro Nochioka, et al.
American Heart Journal|February 28, 2016
Can the optimal type of stent be predicted based on clinical risk factors? A subgroup analysis of the randomized BASKET-PROVE trialGiuseppe Vassalli, Catherine Klersy, Stefano De Servi, et al.
Pageof 8